A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine

Familial Cancer

Volumn 14, Issue 3, 2015, Pages 437-448

  Hansen, Maren F ^a,b   Johansen, Jostein ^a   Bjørnevoll, Inga ^b   Sylvander, Anna E ^b   Steinsbekk, Kristin S ^a   Sætrom, Pål ^a   Sandvik, Arne K ^a,b   Drabløs, Finn ^a   Sjursen, Wenche ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal cancer; Germline mutation; POLE; Polymerase epsilon

Indexed keywords

DNA DIRECTED DNA POLYMERASE EPSILON; EXONUCLEASE; DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN;

ARTICLE; CANCER SUSCEPTIBILITY; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE PREDISPOSITION; ENZYME ACTIVITY; EXOME; GERMLINE MUTATION; HUMAN; OVARY CANCER; PANCREAS CANCER; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SMALL INTESTINE CANCER; AMINO ACID SEQUENCE; COLORECTAL TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MALE; METABOLISM; MOLECULAR GENETICS; MUTATION; OVARY TUMOR; PANCREAS TUMOR; PATHOLOGY; PEDIGREE; SEQUENCE HOMOLOGY; SMALL INTESTINE;

AMINO ACID SEQUENCE; COLORECTAL NEOPLASMS; DNA POLYMERASE II; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INTESTINE, SMALL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PEDIGREE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84941004198     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-015-9803-2     Document Type: Article

References (66)

1. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85. doi:10.1056/NEJM200007133430201
2. Johns LE, Houlston RS (2001) A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 96:2992–3003. doi:10.1111/j.1572-0241.2001.04677.x
3. Grady WM (2003) Genetic testing for high-risk colon cancer patients. Gastroenterology 124:1574–1594. doi:10.1016/S0016-5085(03)00376-7
4. Jasperson KW, Tuohy TM, Neklason DW, Burt RW (2010) Hereditary and familial colon cancer. Gastroenterology 138:2044–2058. doi:10.1053/j.gastro.2010.01.054
5. Lynch HT, Lynch PM, Lanspa SJ et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18. doi:10.1111/j.1399-0004.2009.01230.x
6. Gala M, Chung DC (2011) Hereditary colon cancer syndromes. Semin Oncol 38:490–499. doi:10.1053/j.seminoncol.2011.05.003
7. Palles C, Cazier J-B, Howarth KM et al (2013) Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45:136–144. doi:10.1038/ng.2503
8. Patel SG, Ahnen DJ (2012) Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep 14:428–438. doi:10.1007/s11894-012-0280-6
9. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25:1754–1760. doi:10.1093/bioinformatics/btp324
10. Broad Institute Picard Tools. http://broadinstitute.github.io/picard/. Accessed 22 Jan 2015
11. Li H, Handsaker B, Wysoker A et al (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. doi:10.1093/bioinformatics/btp352
12. DePristo MA, Banks E, Poplin R et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491–498. doi:10.1038/ng.806
13. Van der Auwera GA, Carneiro MO, Hartl C et al (2013) From FastQ data to high-confidence variant calls: the genome analysis toolkit best practices pipeline. In: Bateman A, Pearson WR, Stein LD et al (eds) Current protocols in bioinformatics, 43rd edn. Wiley, Hoboken, pp 1–11
14. McKenna A, Hanna M, Banks E et al (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. doi:10.1101/gr.107524.110
15. How-to/exome analysis—SEQwiki. http://seqanswers.com/wiki/How-to/exome_analysis. Accessed 22 Jan 2015
16. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164. doi:10.1093/nar/gkq603
17. Vigeland MD Filtus. http://folk.uio.no/magnusv/filtus.html. Accessed 22 Jan 2015
18. Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185:862–864
19. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A (2010) Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res 20:110–121. doi:10.1101/gr.097857.109
20. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081. doi:10.1038/nprot.2009.86
21. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362. doi:10.1038/nmeth.2890
22. Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249. doi:10.1038/nmeth0410-248
23. Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118. doi:10.1093/nar/gkr407
24. Sievers F, Wilm A, Dineen D et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. doi:10.1038/msb.2011.75
25. Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42:W320–W324. doi:10.1093/nar/gku316
26. Shevelev IV, Hübscher U (2002) The 3′ 5′ exonucleases. Nat Rev Mol Cell Biol 3:364–376. doi:10.1038/nrm804
27. Marchler-Bauer A, Zheng C, Chitsaz F et al (2013) CDD: conserved domains and protein three-dimensional structure. Nucleic Acids Res 41:D348–D352. doi:10.1093/nar/gks1243
28. Forbes SA, Beare D, Gunasekaran P et al (2014) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805–D811. doi:10.1093/nar/gku1075
29. Cambridge M Exome Aggregation Consortium (ExAC). http://exac.broadinstitute.org/. Accessed 1 Dec 2014
30. Sherry ST, Ward MH, Kholodov M et al (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308–311
31. Hogg M, Osterman P, Bylund GO et al (2014) Structural basis for processive DNA synthesis by yeast DNA polymerase ɛ. Nat Struct Mol Biol 21:49–55. doi:10.1038/nsmb.2712
32. Rohlin A, Zagoras T, Nilsson S et al (2014) A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol 45:77–81
33. Valle L, Hernández-Illán E, Bellido F et al (2014) New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 23:3506–3512. doi:10.1093/hmg/ddu058
34. Smith CG, Naven M, Harris R et al (2013) Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Hum Mutat 34:1026–1034. doi:10.1002/humu.22333
35. Beese LS, Steitz TA (1991) Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J 10:25–33
36. Brautigam CA, Steitz TA (1998) Structural principles for the inhibition of the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I by phosphorothioates. J Mol Biol 277:363–377. doi:10.1006/jmbi.1997.1586
37. Derbyshire V, Grindley ND, Joyce CM (1991) The 3′-5′ exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction. EMBO J 10:17–24
38. Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH (1996) Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 35:16621–16629. doi:10.1021/bi961552q
39. Soengas MS, Esteban JA, Lázaro JM et al (1992) Site-directed mutagenesis at the Exo III motif of phi 29 DNA polymerase; overlapping structural domains for the 3′-5′ exonuclease and strand-displacement activities. EMBO J 11:4227–4237
40. Hwang YT, Liu BY, Coen DM, Hwang CB (1997) Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 71:7791–7798
41. Elisseeva E, Mandal SS, Reha-Krantz LJ (1999) Mutational and pH studies of the 3′→5′ exonuclease activity of bacteriophage T4 DNA polymerase. J Biol Chem 274:25151–25158. doi:10.1074/jbc.274.35.25151
42. Freemont PS, Friedman JM, Beese LS et al (1988) Cocrystal structure of an editing complex of Klenow fragment with DNA. Proc Natl Acad Sci USA 85:8924–8928
43. Lam WC, Van der Schans EJ, Joyce CM, Millar DP (1998) Effects of mutations on the partitioning of DNA substrates between the polymerase and 3′-5′ exonuclease sites of DNA polymerase I (Klenow fragment). Biochemistry 37:1513–1522. doi:10.1021/bi9720181
44. Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. doi:10.1158/2159-8290.CD-12-0095
45. Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. doi:10.1126/scisignal.2004088
46. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337. doi:10.1038/nature11252
47. Stenzinger A, Pfarr N, Endris V et al (2014) Mutations in POLE and survival of colorectal cancer patients—link to disease stage and treatment. Cancer Med. doi:10.1002/cam4.305
48. Albertson TM, Ogawa M, Bugni JM et al (2009) DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci USA 106:17101–17104. doi:10.1073/pnas.0907147106
49. Spier I, Holzapfel S, Altmüller J et al (2014) Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. doi:10.1002/ijc.29396
50. Tingstedt B, Weitkämper C, Andersson R (2011) Early onset pancreatic cancer—comparison against matched controls. Ann Gastroenterol 24:206–212
51. Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701–706. doi:10.1007/s11605-007-0384-8
52. Tran PT, Erdeniz N, Symington LS, Liskay RM (2004) EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst) 3:1549–1559. doi:10.1016/j.dnarep.2004.05.015
53. Shen B, Nolan JP, Sklar LA, Park MS (1997) Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res 25:3332–3338
54. Liberti SE, Larrea AA, Kunkel TA (2013) Exonuclease 1 preferentially repairs mismatches generated by DNA polymerase α. DNA Repair (Amst) 12:92–96. doi:10.1016/j.dnarep.2012.11.001
55. Hombauer H, Campbell CS, Smith CE et al (2011) Visualization of eukaryotic DNA mismatch repair reveals distinct recognition and repair intermediates. Cell 147:1040–1053. doi:10.1016/j.cell.2011.10.025
56. Tran HT, Gordenin DA, Resnick MA (1999) The 3′→5′ exonucleases of DNA polymerases delta and epsilon and the 5′→3′ exonuclease Exo1 have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae. Mol Cell Biol 19:2000–2007
57. Talseth-Palmer BA, Wijnen JT, Brenne IS et al (2013) Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer 132:1556–1564. doi:10.1002/ijc.27843
58. Cybulski C (2004) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677–2679. doi:10.1158/0008-5472.CAN-04-0341
59. Dong X, Wang L, Taniguchi K et al (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270–280. doi:10.1086/346094
60. Gronwald J, Cybulski C, Piesiak W et al (2009) Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 100:1508–1512. doi:10.1038/sj.bjc.6605038
61. Huijts PEA, Hollestelle A, Balliu B et al (2014) CHEK2* 1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer. Eur J Hum Genet 22:46–51. doi:10.1038/ejhg.2013.85
62. Meijers-Heijboer H, Wijnen J, Vasen H et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314
63. Wasielewski M, Vasen H, Wijnen J et al (2008) CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Clin Cancer Res 14:4989–4994. doi:10.1158/1078-0432.CCR-08-0389
64. Rabbani B, Tekin M, Mahdieh N (2014) The promise of whole-exome sequencing in medical genetics. J Hum Genet 59:5–15. doi:10.1038/jhg.2013.114
65. DeRycke MS, Gunawardena SR, Middha S et al (2013) Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. Cancer Epidemiol Biomarkers Prev 22:1239–1251. doi:10.1158/1055-9965.EPI-12-1226
66. Gylfe AE, Katainen R, Kondelin J et al (2013) Eleven candidate susceptibility genes for common familial colorectal cancer. PLoS Genet 9:e1003876. doi:10.1371/journal.pgen.1003876